| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DIRAS2 |
| Uniprot No | Q96HU8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-199aa |
| 氨基酸序列 | MPEQSNDYRVAVFGAGGVGKSSLVLRFVKGTFRESYIPTVEDTYRQVISCDKSICTLQITDTTGSHQFPAMQRLSISKGHAFILVYSITSRQSLEELKPIYEQICEIKGDVESIPIMLVGNKCDESPSREVQSSEAEALARTWKCAFMETSAKLNHNVKELFQELLNLEKRRTVSLQIDGKKSKQQKRKEKLKGKCVIM |
| 分子量 | 48.9 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人DIRAS2蛋白的参考文献示例(文献为虚构，仅供示例参考)：
1. **《DIRAS2 regulates autophagy and apoptosis in breast cancer cells》**
- 作者：Li, X. et al.
- 摘要：研究通过体外表达重组人DIRAS2蛋白，揭示了其通过抑制mTOR通路激活自噬，并诱导乳腺癌细胞凋亡的分子机制。
2. **《Structural characterization of recombinant human DIRAS2 and its GTPase activity》**
- 作者：Wang, Y. et al.
- 摘要：首次报道了重组DIRAS2蛋白的晶体结构，证明其具有独特的GTP结合域，并发现其GTPase活性显著低于其他RAS家族成员。
3. **《DIRAS2 suppresses tumor growth by modulating the ERK/MAPK pathway》**
- 作者：Chen, Z. et al.
- 摘要：在小鼠模型中验证重组DIRAS2蛋白的抗肿瘤效果，表明其通过抑制ERK/MAPK信号通路延缓黑色素瘤进展。
4. **《Development of a high-yield expression system for recombinant human DIRAS2 in E. coli》**
- 作者：Zhang, H. et al.
- 摘要：优化DIRAS2蛋白在大肠杆菌中的可溶性表达策略，并建立高效纯化方法，为其功能研究提供可靠工具。
(注：上述文献为模拟内容，实际引用请通过学术数据库检索确认。)
Recombinant human DIRAS2 (DIRAS Family GTPase 2) is a protein encoded by the DIRAS2 gene, belonging to the RAS GTPase superfamily. Unlike classical RAS oncoproteins, DIRAS2 is classified as a tumor suppressor and shares structural homology with the inhibitory GTPase subfamily, featuring conserved G domain motifs critical for GTP binding and hydrolysis. It regulates intracellular signaling pathways involved in cell proliferation, autophagy, and vesicle trafficking. DIRAS2 is predominantly expressed in the brain, with emerging roles in neuronal development and neurodegenerative disorders. Studies suggest its downregulation in certain cancers, implicating potential tumor-suppressive functions through mTOR pathway modulation or apoptosis induction.
The recombinant form, produced via bacterial or mammalian expression systems, enables functional studies by providing purified, bioactive protein for in vitro assays. This facilitates exploration of DIRAS2’s molecular interactions, such as GTPase activity or effector protein binding, and its therapeutic potential. Additionally, recombinant DIRAS2 aids in antibody development for diagnostic applications. Research continues to clarify its precise mechanisms in cancer biology and neurology, positioning it as a promising target for drug discovery. Its unique regulatory profile within the RAS family underscores both academic and clinical relevance.
×
